OpenAI purchases Orchestra Bio, a firm coordinating drug development
Orchestra's team and technology will go into OpenAI's Rosalind life sciences model and related Workbench tool.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
The AI company bought Orchestra Bio, a platform that tracks drug development timelines and delays. OpenAI plans to fold Orchestra's staff and technology into Rosalind, its life sciences AI model. The related Rosalind Workbench tool is intended to help scientists plan experiments and analyze outcomes.
Why it matters
The deal raises oversight questions for pharmaceutical teams. It reflects AI developers competing to change how medicines are discovered.
Timeline
- Oct 20, 3:32 PM ET: OpenAI acquires Orchestra Bio, whose platform tracks drug development timelines.
- Oct 20, 4:35 PM ET: OpenAI says it will add Orchestra's team and technology to Rosalind and the Workbench tool.
- Oct 21, 10:47 AM ET: OpenAI announces the deal on Tuesday alongside a ChatGPT feature that lets users lock conversations.
Coverage
- Alcon and OpenAI make acquisitions; Tezspire's latest Phase 3 win (ENDPOINTS)
- OpenAI Adds Locked Chats to ChatGPT and Acquires Orchestra Bio to Strengthen Life Sciences AI (theaiinsider.tech)
- OpenAI Drug Development AI Expands With Orchestra Bio Acquisition (en.cryptonomist.ch)
- OpenAI buys AI biotech Orchestra Bio to expand into drug development (medwatch.com)
- OpenAI acquires Orchestra Bio to build AI agents that speed up drug development (the-decoder.com)
- OpenAI Acquires Orchestra Bio to Accelerate Drug Development With AI-Powered Rosalind (kingy.ai)
- OpenAI buys Orchestra Bio to expand drug development tools (thepharmaletter.com)
- OpenAI acquires Orchestra Bio to bring AI agents into drug development (siliconangle.com)
- OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work (Jose Antonio Lanz)
- OpenAI acquires startup Orchestra Bio to beef up its biotech business (techcrunch.com)
- OpenAI acquires drug tool to speed slow drug development workflows (interestingengineering.com)
- OpenAI Buys Orchestra Bio to Expand AI’s Role in Drug Development (citybiz.co)
- OpenAI Bets on Accelerating Drug Development Timelines with Orchestra Bio (pharmtech.com)
- OpenAI acquires Orchestra Bio in AI push for new drugs (TradingView)
- OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports (Investing.com)
More from Technology & AI
- China puts humanoid robots to work serving food and sorting parcels
- Newsom proposes sweeping AI safety rules for Washington
- Google releases Gemini 4 Neon AI model with million-token context
- Microsoft and Intel widen their cloud chip partnership
- Google DeepMind rolls out Genie 4 to select subscribers
- AI helped AMD shorten chip design work, OpenAI says